Merck KGaA, Darmstadt, Germany, Awarded Australian CRISPR Nickase Patent for Foundational Genome-Editing Technology

Merck KGaA, Darmstadt, Germany, today announced that the Australian Patent Office has allowed the company’s patent application for the use of paired CRISPR nickases. 15 AUG 2018 | DARMSTADT, GERMANY Patent covers paired Cas9 nickase technology to reduce off-target effects, advance gene therapy and research Expands company’s foundational CRISPR cutting and integration IP necessary to correct genetic... Read more

After More Than Four Decades at Merck KGaA, Darmstadt, Germany: Walter Galinat to Retire

09 AUG 2018 | DARMSTADT, GERMANY Darmstadt, Germany, August 9, 2018 – The Personnel Committee of the Board of Partners of E. Merck KG, Darmstadt, Germany has resolved by best mutual agreement with Walter Galinat (62) to end his contract as a general partner of E. Merck KG, Darmstadt, Germany and Executive Board member of Merck KGaA, Darmstadt, Germany.... Read more

Merck KGaA, Darmstadt, Germany, Announces Future Insight Prize of up to € 1 Million for Groundbreaking Scientific Work

17 JUL 2018 | DARMSTADT, GERMANY First prize to be awarded 2019 for work on a visionary product to protect humanity from newly emerging viral diseases Merck KGaA, Darmstadt, Germany, committed to “Future Insight Prize” for the next 35 years Announcement made at “Curious2018 – Future Insight” conference premiere Darmstadt, Germany, July 17, 2018 – Merck KGaA,... Read more

MilliporeSigma to Expand Operations in Gillingham, UK

Jul 02, 2018 Company to expand distribution centre for Life Science products to support future business growth MilliporeSigma, a leading science and technology company, today announced plans to expand its Gillingham, UK distribution centre. The €9 million investment will boost distribution capabilities for the business. Anticipated to open in early 2019, the new facility will... Read more

MilliporeSigma Signs Exclusive Agreement with HistoCyte Laboratories to Distribute Pathology Technology

News Release June 19, 2018 Your Contact: Karen Tiano +1 978 495 0093 MilliporeSigma to distribute cell line reference materials in U.S. and other select geographies Reference products available in cost-effective, easy-fit blocks for laboratory workflows Products to be available through e-commerce platform, SigmaAldrich.com Burlington, Massachusetts, June 19, 2018 — MilliporeSigma today announced that it has... Read more

Merck KGaA, Darmstadt, Germany Provides Update on Tepotinib Phase II Results in Advanced Hepatocellular Carcinoma

Primary endpoints met in two clinical trials for investigational targeted therapy, tepotinib, as a monotherapy in MET-positive, advanced hepatocellular carcinoma (HCC) with Child-Pugh Class A liver function These data provide further evidence of tepotinib activity in patients with MET-positive advanced cancers Given evolving standard of care in HCC, Merck KGaA, Darmstadt, Germany will assess the... Read more

Merck KGaA, Darmstadt, Germany Drives Thought Leadership in Ethical Gene Editing

Co-authored paper, “Ethical Considerations in the Manufacture, Sale and Distribution of Genome-Editing Technologies,” accepted in leading bioethics journal Highlights importance of science-based bioethics in genome editing and novel processes to ensure products meet the highest standards  Darmstadt, Germany, June 12, 2018 – Merck KGaA, Darmstadt, Germany, a leading science and technology company and leader in... Read more

Merck KGaA, Darmstadt, Germany Completes Third and Final Registration Phase under the European Chemicals Regulation REACH

June 6, 2018 Your Contact: Gangolf Schrimpf +49 6151 72-9591 Merck KGaA, Darmstadt, Germany Completes Third and Final Registration Phase under the European Chemicals Regulation REACH More than 1,000 registration dossiers successfully submitted for safe use Darmstadt, Germany, June 6, 2018 — Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced that it... Read more

MilliporeSigma Brings Biotechs Closer to Drug Therapy Production and Commercialization

News Release June 5, 2018 Your Contact: Karen Tiano +1 978 495 0093 MilliporeSigma Brings Biotechs Closer to Drug Therapy Production and Commercialization Opens North America’s first BioReliance® End-to-End Biodevelopment Center to help customers with biopharmaceutical manufacturing processes Accelerates clinical development from DNA to market “Advance Biotech Grant Program” expands global biotech commitment to help... Read more

MilliporeSigma Announces Collaboration with Solvias for New Pyrogen Detection Kit

News Release May 17, 2018 Your Contact: Karen Tiano +1 978 495 0093 Only cell-line-based Monocyte Activation Test (MAT) kit on the market Detects broad spectrum of pyrogens and offers high reproducibility, sensitivity Eliminates the need for live animal testing Burlington, Massachusetts, May 17, 2018 — MilliporeSigma today announced a collaboration with Solvias, a Swiss contract... Read more